Last reviewed · How we verify

WiSP Wissenschaftlicher Service Pharma GmbH — Portfolio Competitive Intelligence Brief

WiSP Wissenschaftlicher Service Pharma GmbH pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Anthracycline/dexamethasone-based induction chemotherapy Anthracycline/dexamethasone-based induction chemotherapy phase 3 Combination chemotherapy regimen DNA (anthracycline); glucocorticoid receptor (dexamethasone) Oncology
Dexamethasone for control of symptoms Dexamethasone for control of symptoms phase 3 Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR) Immunology / Inflammation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 2 shared drug classes
  2. University Hospital, Bordeaux · 2 shared drug classes
  3. Amgen · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Beijing Friendship Hospital · 1 shared drug class
  6. Cancer Trials Ireland · 1 shared drug class
  7. Centre Hospitalier Universitaire Dijon · 1 shared drug class
  8. Asan Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for WiSP Wissenschaftlicher Service Pharma GmbH:

Cite this brief

Drug Landscape (2026). WiSP Wissenschaftlicher Service Pharma GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wisp-wissenschaftlicher-service-pharma-gmbh. Accessed 2026-05-17.

Related